Bill:  SB 241 
Legislative Session: 88(R) Council Document: 88R 458 KKR-D
Add to Bill List
Last Action:05/27/2023 E Effective on . . . . . . . . . . . . . . .
Caption Version:Enrolled
Caption Text:Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability.
Author:Perry
Sponsor:Talarico
Subjects:Health--Other Diseases & Medical Conditions (I0383)
Insurance--Health & Accident (I0422)
DIABETES (S0486)
MEDICINE & PRESCRIPTION DRUGS (S7338)
HEALTH & HUMAN SERVICES COMMISSION (V0177)
Companion:HB 2529 by Talarico, Identical
Senate Committee:Health & Human Services
Status:Out of committee
Vote:Ayes=9   Nays=0   Present Not Voting=0   Absent=0
House Committee:Public Health
Status:Out of committee
Vote:Ayes=9   Nays=0   Present Not Voting=0   Absent=2
Actions: (ascending date order)
Viewing Votes: Most Recent House Vote | Most Recent Senate Vote
Description Comment Date       Time       Journal Page
S   Received by the Secretary of the Senate      11/16/2022    
S   Filed      11/16/2022    
S   Read first time      02/15/2023     166
S   Referred to Health & Human Services      02/15/2023     166
S   Scheduled for public hearing on . . .      03/08/2023    
S   No action taken in committee      03/08/2023    
S   Scheduled for public hearing on . . .      03/15/2023    
S   Considered in public hearing      03/15/2023    
S   Testimony taken in committee      03/15/2023    
S   Vote taken in committee      03/15/2023    
S   Reported favorably as substituted      03/20/2023     508
S   Recommended for local & uncontested calendar      03/20/2023    
S   Committee report printed and distributed      03/20/2023   03:09 PM 
S   Placed on intent calendar      03/22/2023    
S   Rules suspended-Regular order of business      03/23/2023     589
S   Read 2nd time      03/23/2023     589
S   Amendment(s) offered   FA1 Perry   03/23/2023     589
S   Amended      03/23/2023     589
S   Vote recorded in Journal      03/23/2023     589
S   Passed to engrossment as amended      03/23/2023     589
S   Vote recorded in Journal      03/23/2023     589
S   Three day rule suspended      03/23/2023     589
S   Record vote      03/23/2023     589
S   Read 3rd time      03/23/2023     589
S   Passed      03/23/2023     589
S   Record vote      03/23/2023     589
S   Reported engrossed      03/23/2023     618
H   Received from the Senate      03/27/2023     912
H   Read first time      04/10/2023     1300
H   Referred to Public Health      04/10/2023   03:28 PM  1300
H   Considered in formal meeting      05/03/2023    
H   Recommended to be sent to Local & Consent      05/03/2023    
H   Reported favorably w/o amendment(s)      05/03/2023    
H   Comte report filed with Committee Coordinator      05/06/2023     3468
H   Committee report distributed      05/07/2023   06:38 PM 
H   Comm. report sent to Local & Consent Calendar      05/08/2023    
H   Considered in Local & Consent Calendars      05/10/2023    
H   Placed on Local, Consent, and Res. Calendar      05/12/2023    
H   Read 2nd time      05/12/2023     4078
H   Passed to 3rd reading      05/12/2023     4078
H   Nonrecord vote recorded in Journal      05/12/2023     4078
H   Read 3rd time      05/12/2023     4099
H   Passed      05/12/2023     4099
H   Record vote   RV#1580   05/12/2023     4099
H   Nonrecord vote recorded in Journal      05/12/2023     4099
S   House passage reported      05/15/2023     1875
S   Reported enrolled      05/15/2023     1929
S   Signed in the Senate      05/16/2023     1931
H   Signed in the House      05/16/2023     4384
E   Sent to the Governor      05/16/2023     1988
E   Signed by the Governor      05/27/2023     3176
E   Effective on . . . . . . . . . . . . . . .   September 1, 2024   05/27/2023